TabletsClinical Overview
HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally once daily with water, with or without food. Atorvastatin and Rosuvastatin can be taken at any time of day due to prolonged half-lives, but evening administration is traditional. Maintain regular daily dosing.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Myalgia, headache, nausea, diarrhea, abdominal pain, mild elevation of transaminases, nasopharyngitis. Rare/Severe: Rhabdomyolysis with myoglobinuria and acute renal failure, immune-mediated necrotizing myopathy (IMNM), drug-induced liver injury, and cognitive impairment.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in active liver disease, unexplained persistent elevation of serum transaminases, and during pregnancy and lactation. Patients must report any unexplained muscle pain, tenderness, or weakness immediately, especially with dark tea-colored urine. Periodic liver function tests are recommended.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified cardiologist/pharmacist before initiating, altering, or substituting any cardiovascular medication.
Atorvastatin Tablets 10mg
HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).
Atorvastatin 10mg + Clopidogrel 75mg Capsules
Statin and Antiplatelet (Aspirin +/- Clopidogrel) cardiovascular polypill formulation. Unites intensive lipid lowering and plaque stabilization (via HMG-CoA reductase inhibition) with antiplatelet thrombus prevention (via irreversible COX-1 inhibition and/or ADP P2Y12 platelet receptor blockade). Indicated for secondary prevention in coronary artery disease, acute coronary syndrome, post-percutaneous coronary intervention (PCI/stenting), and ischemic stroke.
Atorvastatin 10mg + Fenofibrate 160mg Tablets
Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.
Atorvastatin Tablets 40 mg
HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).